Can the EC Boost Europe's Competitiveness?
The European Commission is trying to turn Europe into a more competitive player in the global pharmaceutical market, through speeding up and streamlining the pre-market drug approvals process, including implementation of a new US-style "fast-track" alternative. But without simultaneous reforms in pricing and reimbursement by member states, loosening of marketing restrictions isn't likely to have much impact.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.